Meeting
2022 ASCO Annual Meeting
Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress).
Authors
Amita Patnaik
START San Antonio, San Antonio, TX
Amita Patnaik , Nehal J. Lakhani , Ping Xu , Natalya N. Nazarenko , Justin A Call
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT05194072
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3155)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3155
Abstract #
TPS3155
Poster Bd #
145a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors.
First Author: Sun Young Rha
Poster
2019 ASCO Annual Meeting
Phase 1a/1b study of first-in-class B7-H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors.
First Author: Jasgit C. Sachdev
Poster
2013 ASCO Annual Meeting
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
First Author: Michael Ong
Poster
2022 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of CLN-619 (anti-MICA/MICB antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: John D. Powderly